Skip to main content
logo
Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,005.00
+70.00 (1.78%)
Sep 18, 2026, 3:30 PM KST

Bukwang Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
8,77812,558-2,641-31,330-2,475-916.62
Depreciation & Amortization
5,1085,4894,1064,2925,1174,843
Loss (Gain) From Sale of Assets
-61.95-374.4-53.75-30.64-52.25-220.05
Asset Writedown & Restructuring Costs
2,9432,9439,585---
Loss (Gain) From Sale of Investments
573.936,009-738.9564.4567.47-90.53
Loss (Gain) on Equity Investments
4.06-18.33-343.131,501-58.571,361
Stock-Based Compensation
13.213.2-3.53147.4944.333.41
Provision & Write-off of Bad Debts
97.24-22.4-554.54-4,8972,9021,694
Other Operating Activities
9,1647,454379.98-3,3733,261917.18
Change in Accounts Receivable
-9,311-4,03912,93357,117-423.7411,554
Change in Inventory
-3,534-8,58514,296-18,388208.4312,182
Change in Accounts Payable
-125.342,4752,432-14,1609,154-2,735
Change in Other Net Operating Assets
-8,172-2,436-5,035-806.65-1,782-2,066
Operating Cash Flow
5,47821,46434,362-9,36216,46126,525
Operating Cash Flow Growth
-85.53%-37.54%---37.94%3567.88%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-7,014-7,257-1,938-2,835-4,298-785.05
Sale of Property, Plant & Equipment
-10.78737.745.52142.271.27388.45
Divestitures
--369.75238.89--
Sale (Purchase) of Intangibles
-2,705-3,937-629.25267.3-692.11-4.47
Investment in Securities
-5,653-82,225-25,575-152.851,5885,150
Other Investing Activities
-30,000-3,000020180-0
Investing Cash Flow
-50,383-95,682-27,727-2,319-3,1514,749

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
--10,000-10,000-
Long-Term Debt Issued
---80,000--
Total Debt Issued
--10,00080,00010,000-
Short-Term Debt Repaid
---10,000--10,000-20,000
Long-Term Debt Repaid
--459.42-63,602-447.86-433.92-452.42
Total Debt Repaid
-492.81-459.42-73,602-447.86-10,434-20,452
Net Debt Issued (Repaid)
-492.81-459.42-63,60279,552-433.92-20,452
Issuance of Common Stock
88,15888,158--100-
Repurchase of Common Stock
------516.19
Dividends Paid
-12,333-4,933---6,845-6,225
Other Financing Activities
-2,896-2,981-4,049-2,714-469.66-290.94
Financing Cash Flow
72,43579,784-67,65176,839-10,398-27,485

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
6.18551.43-120.02552.82-172.98-303.37
Net Cash Flow
27,5376,117-61,13665,7102,7403,486

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1,53614,20632,424-12,19612,16325,740
Free Cash Flow Growth
--56.18%---52.74%-
Free Cash Flow Margin
-0.71%7.08%20.25%-9.69%6.37%14.11%
Free Cash Flow Per Share
-15.71171.97473.65-178.17177.69375.98
Levered Free Cash Flow
-22,942-9,886-34,26259,1499,28525,241
Unlevered Free Cash Flow
-20,507-7,451-30,20661,52910,38526,121

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
2,8962,9814,0321,139147.12290.94
Cash Income Tax Paid
--8,4421,588900.44,1168,933
Change in Working Capital
-21,142-12,58624,62623,7637,15618,934